Free Trial

RxSight (RXST) Competitors

RxSight logo
$8.00 -0.46 (-5.44%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$8.11 +0.11 (+1.39%)
As of 07/11/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RXST vs. NVCR, LMAT, EYE, ENOV, CNMD, AORT, CDRE, TNDM, ESTA, and LQDA

Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), Tandem Diabetes Care (TNDM), Establishment Labs (ESTA), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry.

RxSight vs. Its Competitors

NovoCure (NASDAQ:NVCR) and RxSight (NASDAQ:RXST) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

NovoCure has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.

In the previous week, RxSight had 41 more articles in the media than NovoCure. MarketBeat recorded 46 mentions for RxSight and 5 mentions for NovoCure. NovoCure's average media sentiment score of 0.57 beat RxSight's score of -0.22 indicating that NovoCure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NovoCure
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
RxSight
1 Very Positive mention(s)
5 Positive mention(s)
15 Neutral mention(s)
10 Negative mention(s)
4 Very Negative mention(s)
Neutral

RxSight has lower revenue, but higher earnings than NovoCure. RxSight is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoCure$605.22M3.24-$168.63M-$1.51-11.66
RxSight$139.93M2.32-$27.45M-$0.67-11.94

NovoCure currently has a consensus price target of $32.43, indicating a potential upside of 84.25%. RxSight has a consensus price target of $23.90, indicating a potential upside of 198.75%. Given RxSight's higher probable upside, analysts plainly believe RxSight is more favorable than NovoCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NovoCure
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
RxSight
2 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.90

RxSight has a net margin of -17.90% compared to NovoCure's net margin of -26.41%. RxSight's return on equity of -9.54% beat NovoCure's return on equity.

Company Net Margins Return on Equity Return on Assets
NovoCure-26.41% -45.46% -13.34%
RxSight -17.90%-9.54%-8.51%

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 5.5% of NovoCure shares are owned by insiders. Comparatively, 9.6% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

RxSight beats NovoCure on 9 of the 16 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXST vs. The Competition

MetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$343.79M$6.82B$5.62B$9.10B
Dividend YieldN/A1.25%5.24%4.00%
P/E Ratio-11.9425.8228.1020.27
Price / Sales2.3249.57429.7098.72
Price / CashN/A20.9237.4658.16
Price / Book1.154.648.045.49
Net Income-$27.45M$174.76M$3.18B$250.45M
7 Day Performance-39.39%-1.00%3.62%4.78%
1 Month Performance-43.94%-1.49%4.05%7.67%
1 Year Performance-83.24%4.27%30.00%16.43%

RxSight Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXST
RxSight
2.2449 of 5 stars
$8.00
-5.4%
$23.90
+198.8%
-83.9%$343.79M$139.93M-11.94220Trending News
Analyst Forecast
High Trading Volume
NVCR
NovoCure
3.67 of 5 stars
$17.80
-1.1%
$32.83
+84.5%
-0.7%$2.01B$605.22M-11.791,488Analyst Forecast
LMAT
LeMaitre Vascular
2.4884 of 5 stars
$83.05
+0.6%
$97.83
+17.8%
-1.6%$1.87B$219.86M41.94490News Coverage
Positive News
EYE
National Vision
2.5554 of 5 stars
$23.01
-0.7%
$18.67
-18.9%
+88.3%$1.83B$1.82B-69.7313,411News Coverage
Positive News
Analyst Forecast
ENOV
Enovis
2.6299 of 5 stars
$31.36
-1.3%
$58.00
+84.9%
-25.5%$1.82B$2.11B-2.257,367Positive News
Analyst Forecast
CNMD
CONMED
4.427 of 5 stars
$52.10
-0.1%
$62.20
+19.4%
-24.4%$1.61B$1.31B13.713,900
AORT
Artivion
2.6675 of 5 stars
$31.17
-0.1%
$32.00
+2.7%
+18.3%$1.33B$388.54M-62.341,600
CDRE
Cadre
2.99 of 5 stars
$31.94
-0.3%
$37.50
+17.4%
-7.3%$1.30B$567.56M33.622,284
TNDM
Tandem Diabetes Care
4.1289 of 5 stars
$18.64
-1.6%
$33.43
+79.3%
-65.5%$1.26B$940.20M-6.712,650Analyst Forecast
ESTA
Establishment Labs
1.5344 of 5 stars
$42.71
+4.3%
$52.40
+22.7%
-1.6%$1.18B$166.02M-13.781,018Analyst Forecast
LQDA
Liquidia Technologies
3.1703 of 5 stars
$12.46
-4.9%
$26.89
+115.8%
+13.0%$1.12B$14M-7.8950

Related Companies and Tools


This page (NASDAQ:RXST) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners